This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Atuk, N. O. Articles by Vance, M. L. Search for Related Content PubMed PubMed Citation Articles by Atuk, N. O. Articles by Vance, M. L.

Pheochromocytoma in von Hippel-Lindau Disease: Clinical Presentation and Mutation Analysis in a Large, Multigenerational Kindred¹

Nephrology and Endocrinology and Metabolism Divisions, Department of Internal Medicine, University of Virginia Health Sciences Center, Charlottesville, Virginia 22908; and Department of Genetics, University of Pennsylvania, Philadelphia, Pennsylvania

Address all correspondence and requests for reprints to: Nuzhet O. Atuk, Department of Medicine, University of Virginia, Health Sciences Center, Box 133, Charlottesville, Virginia 22908.

The clinical presentation and characterization of the mutation in members of a large kindred with von Hippel-Lindau disease (VHLD) and pheochromocytoma were examined. Twenty-five proven cases of VHLD occurring in four generations of a large kindred have been followed since 1964, and pheochromocytoma has occurred in 17. Symptoms of pheochromocytoma developed at an early age, on average at 12.5 ± 1.3 yr, and definitive diagnosis and treatment of pheochromocytoma occurred at 19.9 ± 2.6 yr. Significantly higher urine catecholamine concentrations were observed in younger patients than in older ones. Mutation analysis was performed in 14 family members, and a new mutation in the VHLD gene was identified in 11; this mutation is a G to T change at nucleotide 658 that results in the substitution of a serine for an alanine residue at position 149 of the polypeptide chain. Seven of the 11 patients with the mutation have VHLD; four, all 10 yr old or less, are asymptomatic and have no evidence of disease, but are at high risk for developing VHLD. These children are being followed closely for clinical and biochemical manifestations. The characterization of this new mutation has permitted identification of family members who are likely to develop VHLD.

This article has been cited by other articles:

				G. Weirich, B. Klein, T. Wohl, D. Engelhardt, and H. Brauch VHL2C Phenotype in a German von Hippel-Lindau Family with Concurrent VHL Germline Mutations P81S and L188V J. Clin. Endocrinol. Metab., November 1, 2002; 87(11): 5241 - 5246. [Abstract] [Full Text] [PDF]

				M. Baghai, G. B. Thompson, W. F. Young Jr, C. S. Grant, V. V. Michels, and J. A. van Heerden Pheochromocytomas and Paragangliomas in von Hippel-Lindau Disease: A Role for Laparoscopic and Cortical-Sparing Surgery Arch Surg, June 1, 2002; 137(6): 682 - 689. [Abstract] [Full Text] [PDF]

				A. L. Bauer, W. R. Paulding, J. B. Striet, P. O. Schnell, and M. F. Czyzyk-Krzeska Endogenous von Hippel-Lindau Tumor Suppressor Protein Regulates Catecholaminergic Phenotype in PC12 Cells Cancer Res., March 1, 2002; 62(6): 1682 - 1687. [Abstract] [Full Text] [PDF]

				G. Eisenhofer, M. M. Walther, T.-T. Huynh, S.-T. Li, S. R. Bornstein, A. Vortmeyer, M. Mannelli, D. S. Goldstein, W. M. Linehan, J. W. M. Lenders, et al. Pheochromocytomas in von Hippel-Lindau Syndrome and Multiple Endocrine Neoplasia Type 2 Display Distinct Biochemical and Clinical Phenotypes J. Clin. Endocrinol. Metab., May 1, 2001; 86(5): 1999 - 2008. [Abstract] [Full Text]

				S. L. Kroll, W. R. Paulding, P. O. Schnell, M. C. Barton, J.W. Conaway, R. C. Conaway, and M. F. Czyzyk-Krzeska von Hippel-Lindau Protein Induces Hypoxia-regulated Arrest of Tyrosine Hydroxylase Transcript Elongation in Pheochromocytoma Cells J. Biol. Chem., October 15, 1999; 274(42): 30109 - 30114. [Abstract] [Full Text] [PDF]